BioCentury
ARTICLE | Financial News

Epic Sciences raises $30 million in series C

July 31, 2014 1:32 AM UTC

Cancer molecular diagnostic company Epic Sciences Inc. (La Jolla, Calif.) raised $30 million in a series C round from new investors RusnanoMedInvest and Arcus Ventures, along with existing investors Domain Associates; Roche Venture Fund; Pfizer Venture Investments. Undisclosed individual investors also participated.

Epic's circulating tumor cell (CTC) technology uses protein and fluorescence in situ hybridization (FISH) markers instead of physical size to separate CTCs from blood samples, which the company believes will prevent destruction of cells and provide more accurate cell counts. Epic's internal pipeline includes diagnostics to help guide treatment and monitor patients' response. The company also has partnerships to develop companion diagnostics for cancer therapeutics with 17 companies. Epic was spun out of the Scripps Research Institute in 2008. ...